.jpeg)
Ireland has earned its reputation as one of the world’s leading pharmaceutical and biopharmaceutical manufacturing hubs. Over decades, the country has successfully attracted some of the most advanced manufacturing operations globally, supported by a highly skilled workforce, a strong regulatory environment and a culture of operational excellence.
For many years, manufacturing excellence has been measured through quality, safety, productivity and supply chain performance. That said, another measure is becoming just as important: environmental performance. Customers, regulators, investors and communities are placing far greater emphasis on how companies manage resources and reduce environmental impact so as to demonstrate long-term sustainability. And water sits at the centre of this conversation.
For pharmaceutical manufacturers, wastewater management has always been a critical operational consideration given its close connection to environmental compliance, process control, site resilience and responsible manufacturing. However, the recast EU Urban Wastewater Treatment Directive (UWWTD) represents a significant shift in how wastewater challenges are addressed and who is expected to contribute to managing them.[1]
The Directive introduces an increased focus on micropollutants - substances present in very small concentrations that can still have environmental impacts - and introduces an Extended Producer Responsibility (EPR) scheme requiring that certain producers, including companies placing medicinal products on the market, must contribute towards the cost of removing these pollutants from urban wastewater.
Understandably, there has been discussion across the pharmaceutical sector about implementation, cost allocation and potential impacts on competitiveness and access to medicines. As these discussions continue, one point is already becoming increasingly clear: the long-term direction is towards greater environmental responsibility and improved removal of micropollutants from wastewater.
For pharmaceutical manufacturers operating here in Ireland, this is not an issue that can be left until legislation is finalised. The companies that begin assessing their wastewater strategies now will be in a much better position to make informed decisions and manage future risks whilst cementing their position as environmental leaders.
A New Chapter in Wastewater Responsibility
The recast Urban Wastewater Treatment Directive entered into force on 1 January 2025 with the aim of strengthening wastewater management across Europe by improving treatment standards and addressing emerging pollutants that traditional wastewater treatment processes may not remove effectively. [2] Historically, wastewater treatment has primarily focused on removing organic matter, nutrients and other conventional pollutants. And while these processes remain essential, scientific understanding has evolved and attention has shifted more toward micropollutants.
Micropollutants are substances found in wastewater at very low concentrations that may still affect aquatic ecosystems or human health depending on their characteristics. They can include pharmaceutical residues, personal care product ingredients, industrial chemicals, microplastics and substances.
For pharmaceutical manufacturers, pharmaceutical residues are particularly relevant. Medicines play a vital role in society, and some environmental presence of active pharmaceutical ingredients is unavoidable due to normal human use, while other substances may arise from manufacturing activities and require careful management. The pharmaceutical industry has already invested significantly in wastewater treatment, process controls and environmental risk management and many manufacturing sites operate sophisticated systems to ensure process wastewater is responsibly managed before discharge.
The recast Directive, however, addresses wastewater treatment at a broader municipal level. It introduces requirements for additional treatment stages, known as quaternary treatment, to remove a wider range of micropollutants from urban wastewater. Quaternary treatment is an additional wastewater treatment step designed to target contaminants that conventional biological treatment may not remove effectively. Depending on the wastewater characteristics, this may involve technologies such as advanced biological processes, activated carbon, ozonation or other advanced treatment approaches, thus representing a significant evolution in wastewater management.[3]
Understanding Extended Producer Responsibility and the Polluter Pays Principle
One of the most significant changes introduced by the Directive is the creation of an Extended Producer Responsibility scheme. Indeed, EPR is not a new concept; it has already been applied in areas such as packaging, batteries and electronic equipment. The underlying principle is that producers should take responsibility for the environmental impacts associated with their products, including contributing towards measures required to manage those impacts.
Under the recast UWWTD, certain pharmaceutical and cosmetic producers placing products on the EU market will be required to contribute financially towards the costs associated with removing micropollutants from wastewater. These costs include investment in treatment infrastructure, operation and maintenance of treatment systems, monitoring requirements and other activities connected with the EPR scheme.
This approach is based on the “polluter pays” principle. Put simply, those contributing to an environmental impact should help fund the measures required to prevent, reduce or manage that impact rather than placing the full burden on taxpayers.
The application of this principle has generated lively discussion within the pharmaceutical sector, with industry groups raising questions around fairness, proportionality and the scientific basis for allocating costs - particularly given that micropollutants can originate from multiple sources.[4]
Such discussions are important because a sustainable approach should recognise the complexity of wastewater pollution and ensure responsibility is allocated appropriately. At the same time, the underlying objective of the Directive remains clear: reducing micropollutants in wastewater and improving environmental protection.
And so, for pharmaceutical manufacturers, the key question is not only what future obligations may look like, but how companies can prepare strategically for a future where environmental performance is increasingly connected to operational success.
The Direction Is Clear
Recent political discussions around aspects of the Directive touch upon concerns raised by some Member States and industry groups regarding cost allocation, competitiveness and potential impacts on medicine supply. It’s important to acknowledge these concerns as good regulation requires careful consideration of evidence, impacts and implementation challenges. That said, companies should not interpret these discussions as a reason to delay action.
The Directive has not been cancelled or abandoned. The broader policy direction remains focused on reducing micropollutants, strengthening wastewater treatment and increasing producer responsibility. Ireland must transpose the Directive into national law by 31 July 2027, with EPR obligations expected to become operational from the end of 2028.[5] And while this may appear some way off, wastewater strategies and infrastructure decisions require careful planning. Understanding wastewater characteristics and selecting appropriate treatment approaches cannot be done effectively last minute. In order to prepare adequately, pharmaceutical manufacturers should begin with mapping and understanding their current position:
- What is in the wastewater?
- Which compounds are present?
- How effective are existing treatment processes?
- Where are opportunities to reduce environmental impact at source?
The responses to the questions will serve as a crucial starting point in identifying the right pathway for future action. After all, if you fail to prepare, you’re preparing to fail!
Why Acting Early Makes Business Sense
Preparing for the recast UWWTD is not simply about meeting a future regulatory requirement. It is about making better decisions today for a sustainable business future. Wastewater treatment systems are long-term assets and they require regular engineering assessment, investment planning, technology evaluation and careful integration with manufacturing operations.
Not only that, but every pharmaceutical site itself is different and wastewater characteristics depend on the products being manufactured, production processes, raw materials, cleaning regimes and existing infrastructure. Two sites producing similar medicines may still have very different wastewater challenges. Understanding wastewater composition provides the foundation for effective decision-making, enabling organisations to identify which substances are present, assess environmental risks, evaluate existing treatment performance and determine where improvements may be needed.
Companies that understand their wastewater today will be better placed to evaluate future options, whether that means optimising current systems, improving source control or considering additional treatment technologies. Those that wait until regulatory deadlines approach may face compressed timelines and limited opportunity to properly evaluate solutions. The pharmaceutical sector has always understood the importance of forward planning and wastewater management should be approached no differently.
Wastewater Is Becoming a Strategic Issue
The role of wastewater management is changing. Historically, wastewater was often viewed primarily through a compliance lens: something that needed to meet permit requirements. That does, of course, remain essential, but the conversation is becoming broader. Today, wastewater sits at the intersection of sustainability, operational resilience, environmental responsibility and corporate reputation.
For global pharmaceutical companies operating in Ireland, environmental performance is increasingly part of the wider value proposition. Companies are under growing pressure to demonstrate progress against ESG commitments and operate responsibly within the communities where they manufacture and smart, sustainable water management is an integral part of that picture.
The Irish pharmaceutical sector has so far built its reputation on world-class standards. The next stage, then, will involve demonstrating that manufacturing excellence extends beyond product quality and operational performance to include environmental leadership and this, consequently, means that wastewater investment should not be viewed purely as a cost. A well-designed wastewater strategy can strengthen resilience, support sustainability commitments, improve confidence around future expansion and help organisations respond effectively as expectations evolve.
Environmental capability is becoming another differentiator in global manufacturing.
Looking Beyond Compliance
One of the risks with environmental regulation is that organisations focus only on achieving minimum requirements. A far stronger approach is to consider the wider opportunity. With that sort of framing, advanced wastewater treatment should ultimately be viewed as an investment in sustainability and long-term resilience.
Given that the pharmaceutical sector has always been driven by innovation, the same principle should hold with regard to environmental challenges. The future of wastewater management will involve a combination of prevention, optimisation and advanced treatment.
Prevention means reducing pollutant generation where possible.
Optimisation means ensuring existing treatment processes perform effectively.
Advanced treatment provides additional capability where conventional approaches cannot achieve the required level of removal. The real objective here is to develop a wastewater strategy that is technically appropriate, economically responsible and aligned with long-term business objectives.
Preparing Ireland’s Pharmaceutical Industry for the Future
Here in Ireland, we have a significant opportunity to demonstrate leadership. The country is home to some of the most advanced pharmaceutical and biopharmaceutical manufacturing facilities in the world and these companies have consistently shown their ability to adapt to regulatory change while also embracing innovation. The recast UWWTD represents another stage in that journey. While discussions around implementation details and cost allocation will continue, the broader direction is clear: environmental performance will become an increasingly important part of responsible manufacturing.
The organisations that prepare early will have an advantage. They will have better information, stronger decision-making capability and more time to develop solutions that meet both environmental and operational objectives. Preparation does not necessarily mean immediate large-scale investment. It means starting the conversation.
It means assessing wastewater characteristics, understanding potential challenges and developing a roadmap.
Supporting Manufacturers Through the Transition
At Veolia, we believe the most effective approach begins with understanding the challenge before identifying the solution. We work with our pharmaceutical partners to understand their wastewater characteristics, assess potential micropollutants, evaluate treatment performance and identify opportunities to optimise their wastewater strategies. This includes supporting organisations as they assess advanced treatment options and prepare for future regulatory requirements.
Advanced biological treatment is one area where innovation continues to develop. Solutions such as eXeno™ demonstrate how biological treatment expertise can help address challenging wastewater streams and support manufacturers preparing for future environmental expectations.
However, technology is only part of the answer.
The right approach begins with data, assessment and understanding. Every manufacturing site has unique requirements, and effective wastewater strategies must be designed around those specific challenges.
Conclusion
The recast Urban Wastewater Treatment Directive represents a significant moment for wastewater management in Ireland’s and, indeed, Europe’s pharmaceutical sector. It introduces new responsibilities, including Extended Producer Responsibility and greater focus on removing micropollutants from wastewater. While discussions around implementation and cost allocation will continue, the long-term direction is clear: environmental performance will become an increasingly important measure of manufacturing excellence.
For Ireland’s pharmaceutical industry, this should not be viewed simply as another regulatory challenge.
It is an opportunity.
An opportunity to strengthen wastewater management, demonstrate environmental leadership and reinforce Ireland’s position as a global centre for sustainable pharmaceutical manufacturing.
The companies that begin preparing now will be better positioned to manage future expectations, make smarter investment decisions and build long-term resilience.
At Veolia, we help pharmaceutical manufacturers understand their wastewater challenges and develop practical strategies for the future.
If your organisation is beginning to assess the implications of the recast UWWTD, we would welcome the opportunity to discuss your wastewater strategy and explore how you can prepare with confidence.
Reach out directly to me or visit our website for more.
